中国肿瘤生物治疗杂志2011，Vol.18Issue(2)：186-189,4.DOI:10.3872/j.issn.1007-385X.2011.02.013
Survivin参与胰腺癌PaTu8988细胞对吉西他滨的耐药
Survivin is involved in drug resistance of pancreatic cancer PaTu8988 cells to gemcitabine
摘要
Abstract
Objective:To explore the expression of apoptotic inhibitory protein survivin in pancreatic cancer cell line PaTu8988, and to study its role in the drug resistance of PaTu8988 cells to gemcitabine (GEM).Methods: The inhibitory effect of GEM (0.01,0.1, 1.0, 2.5, 5.0, and 10.0 μg/ml) on PaTu8988 cells was detected by MTT assay;apoptosis rate of PaTu8988 cells treated with GEM was determined by flow cytometry; and the survivin mRNA expression in PaTu8988 cells was examined by RT-PCR.Results: High dosage of GEM ( ≥1.0 μg/ml) greatly inhibited growth and promoted apoptosis of PaTu8988 cells, while low dosage of GEM (0.01, 0.1 μg/ml) showed no effects.Low dose of GEM time-dependently increased expression of survinin mRNA in PaTu8988 cells; high dosage of GEM gradually inhibited survivin mRNA expression within the first 48 h, and then survivin mRNA expression gradually increased as time went by.Conclusion: Survivin mRNA is highly expressed in pancreatic cancer cell line PaTu8988, which may be one of the reasons for drug resistance to GEM.关键词
胰腺癌/survivin/吉西他滨/耐药/凋亡分类
医药卫生引用本文复制引用
郝利平,王少开,龚涌灵,陈锦飞..Survivin参与胰腺癌PaTu8988细胞对吉西他滨的耐药[J].中国肿瘤生物治疗杂志,2011,18(2):186-189,4.基金项目
南京医科大学医学重点科技发展项目(No.08NMUZ042). （No.08NMUZ042）
